Novel pyrimidine biphenyl derivative with anti-tumor activity as well as preparation method and application thereof

By developing a novel pyrimidine biphenyl derivative, the problem of poor metabolism and selectivity of existing targeted KRAS-PDEδ small molecule inhibitors is solved, and effective inhibition of KRAS-PDEδ is achieved, providing a kind of treatment for pancreatic cancer New drug selection for tumor diseases.

CN118994031APending Publication Date: 2024-11-22JILIN UNIVERSITY +1

Patent Information

Application Number
CN202411108671.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-07-31
Filing Date
2024-08-13
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing small-molecule inhibitors targeting KRAS-PDEδ have poor metabolism and selectivity, making it difficult to effectively treat tumor diseases related to KRAS expression or activity such as pancreatic cancer.

Method used

A novel pyrimidine biphenyl derivative with anti-tumor activity was developed to prepare compounds with good inhibitory effects on KRAS-PDEδ through specific synthetic routes and catalyst combinations, and to prepare compounds with good inhibitory effects on KRAS-PDEδ for the preparation of preventive, therapeutic or adjuvant therapy and KRAS expression. or activity-related drugs for tumor diseases.

Benefits of technology

This novel pyrimidine biphenyl derivative has a good inhibitory effect on KRAS-PDEδ, which can effectively inhibit the downstream signaling pathway of KRAS, thereby exerting the effect of treating tumors, and providing an excellent selective anti-tumor drug selection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994031A_ABST
    Figure CN118994031A_ABST
Patent Text Reader

Abstract

The invention provides a novel pyrimidine biphenyl derivative with antitumor activity as well as a preparation method and application thereof, and relates to the technical field of medicines. The structural general formula of the novel pyrimidine biphenyl derivative is # imgabs0 #, wherein R11 is selected from one of-N (Rb) C (= O) Rc,-N (Rb) S (= O) 2Rc,-C (= O) NRbRc and-S (= O) 2NRbRc; ra is selected from one of hydrogen, deuterium, halogen, hydroxyl, amido, cyano, sulfamido, C1-C6 alkyl and C1-C6 alkoxy; rb is selected from one of hydrogen, deuterium and C1-C6 alkyl; rc is selected from one of C1-C8 alkyl groups, phenyl groups and 5-6-membered heteroaryl groups, wherein the C1-C8 alkyl groups, the phenyl groups and the 5-6-membered heteroaryl groups independently comprise 1, 2 or 3 Ra substituent groups. The compound has a good inhibition effect on tumor cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a novel pyrimidine biphenyl derivative with anti-tumor activity and a preparation method and application thereof. Background Art

[0002] Malignant tumor is one of the most serious diseases that endanger human health. At present, conventional methods for treating tumors include surgical treatment, radiotherapy, chemotherapy and biological regulation therapy. Among them, chemotherapy, as a systemic treatment method, has an important position that cannot be replaced by surgery and radiotherapy in the treatment of malignant tumors. In recent years, the emergence of new chemotherapy drugs has greatly improved the prognosis of tumor patients, but the toxicity of chemotherapy drugs (Kaelin, WG; The Concept of Synthetic Lethality in the Context of Anticancer Therapy. Nat. Rev. Cancer, 2005, 5, 689-698) and the drug resistance of tumor cells to drugs (Green, DR; Evan, GI; A matter of life and death. Cancer Cell, 2002, 1, 19-30) have become two major problems affecting the effect of chemotherapy.

[0003] Pancreatic cancer is a highly malignant digestive system tumor with unknown causes. It is dubbed the "king of cancer" because it is difficult to detect early, has a high degree of malignancy, and progresses rapidly. According to estimates by Cancer, an authoritative journal in cancer research, the incidence of pancreatic cancer has entered the top ten in 2017, and the incidence and mortality figures are quite close. More than 90% of patients who fail to undergo surgery die within one year after diagnosis, and their five-year survival rate is less than 10%. Patients with advanced pancreatic cancer have poor tolerance to chemotherapy regimens, and targeted therapy for pancreatic cancer may become a more effective option. The protein encoded by the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene is a small GTPase that belongs to the RAS superprotein family. It is located on the inner side of the cell membrane and is an effector protein that activates and regulates cell growth and proliferation. KRAS gene mutations can overactivate downstream signals, thus becoming a driving factor in cancer. There are three main mutations in the KRAS gene: G12C, G12V, and G12D. Structural studies have shown that most of these gene mutations interfere with KRAS's ability to hydrolyze GTP. KRAS is the most common mutated gene in pancreatic cancer, present in about 90% of pancreatic cancer patients, making it a very promising target for pancreatic cancer treatment. There are three treatment strategies for KRAS: (1) directly targeting the KRAS protein; (2) indirectly targeting KRAS through protein localization; and (3) affecting the carcinogenic activity of KRAS by interfering with downstream effector proteins and signaling pathways. Due to the lack of binding domains on its surface and the numerous and complex downstream pathway branches, the development of KRAS targeted drugs has been stagnant for a long time until Shokat et al. discovered a molecular screening method for the KRAS G12C mutation (glycine mutation to cysteine) in 2013. Currently, KRAS targeted drugs and related pathway drugs have entered clinical and preclinical research. Unfortunately, all clinically approved KRAS inhibitors currently target KRAS G12C, while G12V and G12D mutations are the main ones in pancreatic cancer, and the proportion of G12C mutations is extremely low. Due to the widespread occurrence of drug resistance, the development of protein-protein interaction (PPI) inhibitors that indirectly target KRAS is receiving more attention. The PPI interaction of KRAS-PDEδ is a new target for the treatment of pancreatic cancer discovered in recent years. Inhibiting the interaction between the two can inhibit the signaling pathway downstream of KRAS, thereby exerting the effect of treating tumors, which is expected to bring good news to many pancreatic cancer patients. However, the existing small molecule inhibitors targeting KRAS-PDEδ have problems such as poor metabolism and selectivity. Therefore, the development of new KRAS-PDEδ inhibitors has become a hot topic in the field of medicinal chemistry research. How to disclose a new organic compound with excellent selectivity and good inhibitory effect on KRAS-PDEδ is an urgent problem to be solved by those skilled in the art. Summary of the invention

[0004] The purpose of the present invention is to provide a novel pyrimidine biphenyl derivative with anti-tumor activity and a preparation method and application thereof, so as to solve the problems of poor metabolism and selectivity of existing small molecule inhibitors targeting KRAS-PDEδ.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a novel pyrimidine biphenyl derivative having anti-tumor activity, wherein the structural formula of the novel pyrimidine biphenyl derivative having anti-tumor activity is as shown in Formula I:

[0007]

[0008] The R 1 One selected from the group consisting of methyl, deuterated methyl and fluoromethyl;

[0009] The R 2 One selected from the group consisting of hydrogen, deuterium, halogen, alkyl and alkoxy;

[0010] The R 3 , R 4 , R 6 , R 7 , R 9 , R 10 , R 12 and R 13 is independently selected from one of hydrogen, deuterium, halogen, hydroxyl, amine, cyano, sulfonamide, C1-C3 alkyl and C1-C3 alkoxy;

[0011] The R 5 One selected from 4-7 membered cyclic amine, 4-7 membered heterocyclic amine and sulfonyl, wherein the 4-7 membered cyclic amine, 4-7 membered heterocyclic amine and sulfonyl independently contain 1, 2 or 3 R a Substituents;

[0012] The R 8 One selected from hydrogen, deuterium and C1-C6 alkyl;

[0013] The R 11 Selected from -N(R b )C(=O)R c 、-N(R b )S(=O) 2 R c 、-C(=O)NR b R c and -S(=O) 2 NR b R c One of;

[0014] Among them, R a One selected from hydrogen, deuterium, halogen, hydroxyl, amine, cyano, sulfonamide, C1-C6 alkyl and C1-C6 alkoxy;

[0015] R b One selected from hydrogen, deuterium and C1-C6 alkyl;

[0016] R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituent.

[0017] The present invention provides a method for preparing the novel pyrimidine biphenyl derivative having anti-tumor activity, comprising the following steps:

[0018] 1) An organic solvent, a catalyst I and potassium acetate are mixed and reacted to obtain a mixture;

[0019] 2) The mixture obtained in step 1) is mixed with Mix with sodium carbonate solution and continue to react to obtain the intermediate

[0020] 3) The intermediate and Catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate are mixed to obtain the target product

[0021]

[0022] Preferably, in step 1) The addition ratio of organic solvent, catalyst I and potassium acetate is 1 mmol: 1.1-2 mmol: 2-10 mL: 0.01-0.1 mmol: 2-4 mmol;

[0023] The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol;

[0024] The catalyst I is tetrakistriphenylphosphine palladium;

[0025] The reaction temperature in step 1) is 95-110° C. and the reaction time is 4-12 hours.

[0026] Preferably, in step 2) The molar volume ratio of sodium carbonate solution is 3-4 mmol: 2.4-3 mL;

[0027] Said and The molar ratio is 1.2 to 2:1;

[0028] The sodium carbonate solution is a saturated sodium carbonate solution;

[0029] The reaction temperature in step 2) is 95-110° C. and the reaction time is 4-12 hours.

[0030] Preferably, in step 3) The molar volume ratio of catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate is 1-1.5 mmol: 1 mmol: 0.1-0.5 mmol: 0.1-0.5 mmol: 1-5 mL: 2-4 mmol;

[0031] The catalyst II is Pd 2 (dba) 3 ;

[0032] The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol;

[0033] The reaction temperature in step 3) is 80-100° C. and the reaction time is 4-12 hours.

[0034] Preferably, the reactions in steps 1) to 3) are independently carried out under an inert atmosphere.

[0035] The present invention also provides a method for preparing the novel pyrimidine biphenyl derivative having anti-tumor activity, comprising the following steps:

[0036] 1) An organic solvent, a catalyst I and potassium acetate are mixed and reacted to obtain a mixture;

[0037] 2) The mixture obtained in step 1) is mixed with Mix with sodium carbonate solution and continue to react to obtain the intermediate

[0038] 3) The intermediate and Catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate are mixed to obtain the target product

[0039]

[0040] 4) Mix with organic solvent and palladium carbon catalyst and introduce hydrogen to react to obtain intermediate product

[0041] 5) The intermediate product Reaction with acid compounds to obtain the target product

[0042]

[0043] In the step 5), the acid compound is a carboxylic acid compound or a sulfonic acid compound;

[0044] The carboxylic acid compound is HOOC-R c , where R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituents;

[0045] The sulfonic acid compound is HOS(=O) 2 -R c , where R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituent.

[0046] Preferably, in step 1) The addition ratio of organic solvent, catalyst I and potassium acetate is 1 mmol: 1.1-2 mmol: 2-10 mL: 0.01-0.1 mmol: 2-4 mmol;

[0047] The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol;

[0048] The catalyst I is tetrakistriphenylphosphine palladium;

[0049] The reaction temperature in step 1) is 95-110° C. and the reaction time is 4-12 hours;

[0050] In the step 2) The molar volume ratio with sodium carbonate solution is 1.2-1.5mmol:1mL;

[0051] Said and The molar ratio is 1.2 to 2:1;

[0052] The sodium carbonate solution is a saturated sodium carbonate solution;

[0053] The reaction temperature in step 2) is 95-110° C. and the reaction time is 4-12 hours.

[0054] Preferably, in step 3) The molar volume ratio of catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate is 1-1.5 mmol: 1 mmol: 0.1-0.5 mmol: 0.1-0.5 mmol: 1-5 mL: 2-4 mmol;

[0055] The catalyst II is Pd 2 (dba) 3 ;

[0056] The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol;

[0057] The reaction temperature in step 3) is 80-100°C and the reaction time is 4-12h;

[0058] In the step 4) The addition ratio of organic solvent, palladium carbon catalyst and hydrogen is 1mmol:1-50mL:10-100mg:1-10bar;

[0059] The reaction time in step 4) is 4 to 12 hours;

[0060] In the step 5) The molar ratio with the acid compound is 1:1.2~2;

[0061] The reaction time of step 5) is 8 to 48 hours.

[0062] The present invention also provides the use of the novel pyrimidine biphenyl derivative with anti-tumor activity in the preparation of anti-tumor drugs.

[0063] The present invention has at least the following beneficial effects:

[0064] The pyrimidine biphenyl compounds provided by the present invention have a good inhibitory effect on KRAS-PDEδ and can be used to prepare drugs for preventing, treating or assisting in treating tumor diseases related to KRAS expression or activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 A in the figure is a comparison of the SERS spectra of the silver magnetic probe mixture after being treated with gradient concentrations of XL-1063 (0-500 μg / mL). Figure 1 B in FIG. 1 is a histogram drawn at the location where the SERS intensity is maximum.

[0066] Figure 2 This is the result of the in vivo inhibition experiment of XL-1063 on BxPC-3 cell line. Figure 2 a in the figure is the tumor tissue photograph obtained from each group; Figure 2b in the figure is the curve of tumor volume change over time in each group; Figure 2 c in the figure is the volume of tumor tissue in each group; Figure 2 d in the figure is the curve of animal weight change over time; Figure 2 e in is the body weight of animals in each group.

[0067] Figure 3 The results of the in vivo inhibition experiment of XL-1063 on MIApaca-2 cell line; Figure 3 A in the figure is the tumor tissue photos obtained from each group; Figure 3 B in the figure is the curve of the volume change of tumor tissue in each group over time; Figure 3 C in the figure is the volume statistics of tumor tissues in each group; Figure 3 D in the figure is the curve of weight change of animals in each group over time; Figure 3 E in the figure is the statistical chart of the weight of animals in each group; Figure 3 F in the figure is a statistical chart of tumor tissue weight in each group.

[0068] Figure 4 H&E and immunohistochemical analysis of BxPC-3 tumor tissue sections.

[0069] Figure 5 H&E and immunohistochemical analysis of MIApaca-2 tumor tissue sections. DETAILED DESCRIPTION

[0070] The present invention provides a novel pyrimidine biphenyl derivative with anti-tumor activity and a preparation method and application thereof, so as to solve the problems of poor metabolism and selectivity of existing small molecule inhibitors targeting KRAS-PDEδ.

[0071] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0072] The present invention provides a novel pyrimidine biphenyl derivative having anti-tumor activity, wherein the structural formula of the novel pyrimidine biphenyl derivative having anti-tumor activity is as shown in Formula I:

[0073]

[0074] The R 1 One selected from the group consisting of methyl, deuterated methyl and fluoromethyl;

[0075] The R 2 One selected from the group consisting of hydrogen, deuterium, halogen, alkyl and alkoxy;

[0076] The R 3 , R 4 , R 6 , R 7 , R 9 , R10 , R 12 and R 13 is independently selected from one of hydrogen, deuterium, halogen, hydroxyl, amine, cyano, sulfonamide, C1-C3 alkyl and C1-C3 alkoxy;

[0077] The R 5 One selected from 4-7 membered cyclic amine, 4-7 membered heterocyclic amine and sulfonyl, wherein the 4-7 membered cyclic amine, 4-7 membered heterocyclic amine and sulfonyl independently contain 1, 2 or 3 R a Substituents;

[0078] The R 8 One selected from hydrogen, deuterium and C1-C6 alkyl;

[0079] The R 11 Selected from -N(R b )C(=O)R c 、-N(R b )S(=O) 2 R c 、-C(=O)NR b R c and -S(=O) 2 NR b R c One of;

[0080] Among them, R a One selected from hydrogen, deuterium, halogen, hydroxyl, amine, cyano, sulfonamide, C1-C6 alkyl and C1-C6 alkoxy;

[0081] R b One selected from hydrogen, deuterium and C1-C6 alkyl;

[0082] R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituent.

[0083] "Hetero" means a heteroatom or a heteroatom group, and the 4- to 7-membered heterocyclic amine and the 5- to 6-membered heteroaryl "hetero" are independently selected from -C(=O)N(R)-, -N(R)-, -NH-, -N-, -O-, -S-, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2- and -N(R)C(=O)N(R)-;

[0084] In any of the above cases, the number of heteroatoms or heteroatoms is independently selected from 1, 2 and 3;

[0085] The heteroatom or heteroatom group can be placed at any interior position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule.

[0086] The present invention provides a method for preparing the novel pyrimidine biphenyl derivative having anti-tumor activity, comprising the following steps:

[0087] 1) An organic solvent, a catalyst I and potassium acetate are mixed and reacted to obtain a mixture;

[0088] 2) The mixture obtained in step 1) is mixed with Mix with sodium carbonate solution and continue to react to obtain the intermediate

[0089] 3) The intermediate and Catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate are mixed to obtain the target product

[0090]

[0091] In the present invention, the synthesis route is shown in Formula II:

[0092]

[0093] In the present invention, in step 1) The addition ratio of (bis-pinacol borate), organic solvent, catalyst I and potassium acetate is 1mmol: 1.1-2mmol: 2-10mL: 0.01-0.1mmol: 2-4mmol, preferably 1mmol: 1.2-1.9mmol: 3-9mL: 0.02-0.09mmol: 2.2-3.8mmol, more preferably 1mmol: 1.3-1.8mmol: 4-8mL: 0.04-0.08mmol: 2.5-3.5mmol, more preferably 1mmol: 1.4-1.6mmol: 5-7mL: 0.05-0.07mmol: 2.8-3.2mmol;

[0094] In the present invention, the organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butanol.

[0095] In the present invention, the catalyst I is tetrakistriphenylphosphine palladium.

[0096] In the present invention, the reaction temperature in step 1) is 95-110°C, preferably 97-108°C, more preferably 100-105°C, and more preferably 103°C; the reaction time is 4-12h, preferably 5-10h, and more preferably 6-8h.

[0097] In the present invention, in step 2) The molar volume ratio of the sodium carbonate solution is 3-4 mmol: 2.4-3 mL, preferably 3.2-3.8 mmol: 2.5-2.9 mL, more preferably 3.4-3.6 mmol: 2.6-2.8 mL, and more preferably 3.5 mmol: 2.7 mL.

[0098] In the present invention, the and The molar ratio of is 1.2 to 2:1, preferably 1.3 to 1.8:1, more preferably 1.4 to 1.6:1, and more preferably 1.5:1.

[0099] In the present invention, the sodium carbonate solution is a saturated sodium carbonate solution.

[0100] In the present invention, the reaction temperature in step 2) is 95-110°C, preferably 98-108°C, more preferably 100-105°C, and more preferably 103°C; the reaction time is 4-12h, preferably 5-10h, and more preferably 6-8h.

[0101] In the present invention, in step 3) The molar volume ratio of catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate is 1-1.5mmol:1mmol:0.1-0.5mmol:0.1-0.5mmol:1-5mL:2-4mmol, preferably 1.1-1.4mmol:1mmol:0.2-0.4mmol:0.2-0.4mmol:2-4mL:2.5-3.5mmol, and further preferably 1.2-1.3mmol:1mmol:0.3mmol:0.3mmol:3mL:3mmol.

[0102] In the present invention, the catalyst II is Pd 2 (dba) 3 .

[0103] In the present invention, the organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butanol.

[0104] In the present invention, the reaction temperature in step 3) is 80-100°C, preferably 83-98°C, more preferably 86-95°C, and more preferably 90-92°C; the reaction time is 4-12h, preferably 5-10h, and more preferably 6-7h.

[0105] In the present invention, the reactions in steps 1) to 3) are independently carried out under an inert atmosphere.

[0106] The present invention also provides a method for preparing the novel pyrimidine biphenyl derivative having anti-tumor activity, comprising the following steps:

[0107] 1) An organic solvent, a catalyst I and potassium acetate are mixed and reacted to obtain a mixture;

[0108] 2) The mixture obtained in step 1) is mixed with Mix with sodium carbonate solution and continue to react to obtain the intermediate

[0109] 3) The intermediate and Catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate are mixed to obtain the target product

[0110] 4) Mix with organic solvent and palladium carbon catalyst and introduce hydrogen to react to obtain intermediate product

[0111] 5) The intermediate product Reaction with acid compounds to obtain the target product

[0112]

[0113] In the present invention, the acid compound in step 5) is a carboxylic acid compound or a sulfonic acid compound;

[0114] The carboxylic acid compound is HOOC-R c , where R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituent.

[0115] The sulfonic acid compound is HOS(=O) 2 -R c , where R cOne selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituent.

[0116] In the present invention, in step 1) The addition ratio of the organic solvent, catalyst I and potassium acetate is 1mmol:1.1~2mmol:2~10mL:0.01~0.1mmol:2~4mmol, preferably 1mmol:1.2~1.8mmol:3~8mL:0.02~0.08mmol:2.5~3.5mmol, and more preferably 1mmol:1.4~1.6mmol:5~7mL:0.04~0.06mmol:2.8~3.0mmol.

[0117] In the present invention, the organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butanol.

[0118] In the present invention, the catalyst I is tetrakistriphenylphosphine palladium.

[0119] In the present invention, the reaction temperature in step 1) is 95-110°C, preferably 98-108°C, more preferably 100-105°C, and more preferably 103°C; the reaction time is 4-12h, preferably 5-10h, and more preferably 6-8h.

[0120] In the present invention, in step 2) The molar volume ratio of the sodium carbonate solution is 1.2 to 1.5 mmol:1 mL, preferably 1.2 to 1.5 mmol:1 mL, and more preferably 1.2 to 1.5 mmol:1 mL.

[0121] In the present invention, the and The molar ratio of is 1.2 to 2:1, preferably 1.4 to 1.8:1, and more preferably 1.5 to 1.6:1.

[0122] In the present invention, the sodium carbonate solution is a saturated sodium carbonate solution.

[0123] In the present invention, the reaction temperature in step 2) is 95-110°C, preferably 98-108°C, more preferably 100-105°C, and more preferably 103°C; the reaction time is 4-12h, preferably 5-10h, and more preferably 6-8h.

[0124] In the present invention, in step 3) The molar volume ratio of catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate is 1-1.5mmol:1mmol:0.1-0.5mmol:0.1-0.5mmol:1-5mL:2-4mmol, preferably 1.1-1.4mmol:1mmol:0.2-0.4mmol:0.2-0.4mmol:2-4mL:2.5-3.5mmol, further preferably 1.2-1.3mmol:1mmol:0.2-0.4mmol:0.2-0.3mmol:3-4mL:2.8-3.2mmol, more preferably 1.2-1.3mmol:1mmol:0.2-0.4mmol:0.2-0.3mmol:3-4mL:2.8-3.2mmol.

[0125] In the present invention, the catalyst II is Pd 2 (dba) 3 .

[0126] In the present invention, the organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butanol.

[0127] In the present invention, the reaction temperature in step 3) is 80-100°C, preferably 83-98°C, more preferably 86-95°C, and more preferably 90-92°C; the reaction time is 4-12h, preferably 5-10h, and more preferably 6-7h.

[0128] In the step 4) The addition ratio of the organic solvent, palladium carbon catalyst and hydrogen is 1mmol:1-50mL:10-100mg:1-10bar, preferably 1mmol:10-45mL:30-90mg:2-9bar, further preferably 1mmol:20-40mL:50-80mg:3-8bar, and more preferably 1mmol:30-35mL:60-70mg:4-7bar.

[0129] In the present invention, the reaction temperature in step 4) is room temperature, and the reaction time is 4 to 12 hours, preferably 5 to 10 hours, and more preferably 6 to 7 hours.

[0130] In the present invention, in step 5) The molar ratio of the polyol to the acid compound is 1:1.2 to 2, preferably 1:1.3 to 1.9, more preferably 1:1.4 to 1.8, and even more preferably 1:1.5 to 1.7.

[0131] In the present invention, the reaction temperature of step 5) is room temperature, and the reaction time is 8 to 48 hours, preferably 14 to 42 hours, more preferably 18 to 36 hours, and more preferably 24 to 32 hours.

[0132] The present invention also provides the use of the novel pyrimidine biphenyl derivative with anti-tumor activity in the preparation of anti-tumor drugs, wherein the tumors include pancreatic cancer, lung cancer and intestinal cancer driven by KRAS-PDEδ interaction.

[0133] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0134] Example 1

[0135] (1) Add 30 mmol of bipinacol borate and 40 mL of 1,4-dioxane to a 250 mL three-necked flask, and add 1 mmol of tetrakistriphenylphosphine palladium (Pd(PPh)) under nitrogen protection. 3 ) 4 , 60mmol potassium acetate and 20mmol p-bromonitrobenzene, stir and heat to 110℃ and reflux for 10h, then stop the reaction, cool the reaction solution to room temperature, add 30mmol 2,4-dichloro-5-methylpyrimidine and 24mL saturated aqueous sodium carbonate solution under nitrogen protection, stir and heat to 100℃, reflux for 9h and stop the reaction, add 200mL water, extract with ethyl acetate three times, the amount of ethyl acetate added each time is 100mL, combine the organic phases, add anhydrous sodium sulfate to dry, evaporate the solvent, separate by column chromatography [V(petroleum ether): V(ethyl acetate) = 4:1], and obtain the target product 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine, mp: 118–120℃; 73%; 1 HNMR (300MHz, CDCl3) δ8.60(d,J=0.7Hz,1H),8.44–8.34(m,2H),7.89–7.79(m,2H),2.41(d,J=0.7Hz,3H); ES-MS m / z 250.1[M+H + ].

[0136] The structural formula of 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine is

[0137] (2) Take 1 mmol of the compound 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine and add it to a 50 mL round-bottom flask. Then add 10 mL of 1,4-dioxane to dissolve it, and then add 1.6 mmol of TsOH·H 2O, 4mmol benzylamine, heated to 110℃, reacted, refluxed for 8h, TLC (thin layer chromatography) monitored the complete consumption of raw materials, the reaction was stopped, the solvent was evaporated, 30mL of water was added, extracted with dichloromethane three times, the amount of dichloromethane used for each extraction was 20mL, the organic phases were combined, anhydrous sodium sulfate was added for drying, the organic phase was evaporated to dryness under reduced pressure, and separated by column chromatography [V (petroleum ether): V (ethyl acetate): V (acetone) = 5:1:1], the target product N-benzyl-5-methyl-4-(4-nitrophenyl) pyrimidin-2-amine, mp: 118–120℃; 58%; 1 H NMR (300MHz, CDCl3) δ8.36–8.27(m,2H),8.25(s,1H),7.78–7.69(m,2H),7.40 –7.26(m,5H),5.55(t,J=5.2Hz,1H),4.66(d,J=5.9Hz,2H),2.20(s,3H); ES-MS m / z 321.0[M+H + ].

[0138] The structural formula of N-benzyl-5-methyl-4-(4-nitrophenyl)pyrimidin-2-amine is

[0139]

[0140] (3) 9.16mmol N-benzyl-5-methyl-4-(4-nitrophenyl)pyrimidin-2-amine and 10mL methanol were added to a 25mL round-bottom flask. 200mg palladium carbon catalyst (manufacturer: Anaiji Chemical; CAS number: 7440-05-3) was added under nitrogen protection, and then hydrogen (5bar) was introduced and stirred at room temperature for 6h. The N-benzyl-5-methyl-4-(4-nitrophenyl)pyrimidin-2-amine 4 was completely consumed by TLC monitoring. The palladium carbon was removed by diatomaceous earth filtration, and the solvent was evaporated under reduced pressure. Ethyl acetate was added and extracted three times, and 20mL of ethyl acetate was added each time. The organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The product was separated by silica gel column chromatography [V (petroleum ether): V (ethyl acetate) = 1:1] to obtain the target product 4-(4-aminophenyl)-N-benzyl-5-methylpyrimidin-2-amine, mp: 101–103°C; 60%; 1 H NMR(300MHz, CDCl3)δ8.11(s,1H),7.53–7.42(m,2H),7.40–7.34(m,5H),6.76 –6.65(m,2H),5.40(t,J=5.3Hz,1H),4.66(d,J=6.0Hz,2H),2.22(s,3H); ES-MS m / z 291.0[M+H + ].

[0141] The structural formula of 4-(4-aminophenyl)-N-benzyl-5-methylpyrimidin-2-amine is

[0142]

[0143] (4) Weigh 14 mmol 4-(4-aminophenyl)-N-benzyl-5-methylpyrimidin-2-amine into a 250 mL round-bottom flask, add 70 mL dichloromethane to dissolve it, and then add 17.5 mmol cinnamic acid, 21 mmol EDCI (1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride), and 7 mmol DMAP (4-dimethylaminopyridine) in sequence. Stir at room temperature for 36 h and stop the reaction. Add 350 mL water and extract with dichloromethane three times, adding 175 mL dichloromethane each time. Combine the organic phases, wash twice with saturated sodium chloride solution, add anhydrous sodium sulfate to dry, evaporate the solvent, and separate by column chromatography [V (petroleum ether): V (ethyl acetate) = 2:1] to obtain the target product N-(4-(2-(benzylamino)-5-methylpyrimidin-4-yl)phenyl)cinnamamide, recorded as compound 1, mp: 185–187 °C; 70%; 1 H NMR (300MHz, CDCl3) δ8.18(s,1H),7.78(d,J=15.5Hz,1H),7.72(dd,J=8.7,3.6Hz,2H),7. 61(dd,J=6.6,2.0Hz,3H),7.55(d,J=3.6Hz,1H),7.53(d,J=2.2Hz,1H),7.38(dd,J=6.0,3 .3Hz,4H),7.35(dd,J=3.3,2.1Hz,1H),7.32(t,J=1.8Hz,1H),7.29(dt,J=7.1,1.9Hz,1H) ,6.58(d,J=15.5Hz,1H),5.50(t,J=5.3Hz,1H),4.67(d,J=5.9Hz,2H),2.22(s,3H); ES-MS m / z 421.2[M+H + ].

[0144] The structural formula of compound 1 is

[0145] Example 2

[0146] (1) Add 30 mmol of bipinacol borate and 40 mL of 1,4-dioxane to a 250 mL three-necked flask, and add 1 mmol of tetrakistriphenylphosphine palladium (Pd(PPh)) under nitrogen protection. 3 ) 4, 60mmol potassium acetate and 20mmol N-(4-bromophenyl)-3,3-dimethylbutanamide, stir and heat to 105℃ and reflux for 8h to stop the reaction, cool the reaction solution to room temperature, add 30mmol 2,4-dichloro-5-methylpyrimidine and 24mL saturated aqueous sodium carbonate solution under nitrogen protection, stir and heat to 95℃, reflux for 10h to stop the reaction, add 200mL water, extract with ethyl acetate three times, the amount of ethyl acetate added each time is 100mL, combine the organic phases, add anhydrous sodium sulfate to dry, evaporate the solvent, separate by column chromatography [V(petroleum ether): V(ethyl acetate)=3:1], and obtain the target product N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)-3,3-dimethylbutanamide, mp: 159–161℃; 73%; 1 H NMR (300MHz, CDCl3) δ8.46(s,1H),7.65(s,4H),7.20(s,1H),2.40(s,3H),2.26(s,2H),1.13(s,9H); ES-MS m / z 318.0[M+H + ].

[0147] The structural formula of N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)-3,3-dimethylbutyramide is

[0148]

[0149] (2) Take 0.63 mmol of the compound N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)-3,3-dimethylbutyramide, 0.6 mmol of aniline, and 0.06 mmol of Pd 2 (dba) 3 , 0.06mmol XPhos (2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl) and 1.8mmol K 2 CO 3 In a 50mL three-necked flask, place it under positive nitrogen pressure, and perform three vacuum nitrogen replacement cycles under high vacuum. Add 6mL of tert-butanol under positive nitrogen pressure and react at 90°C for 9h. After the reaction, add 50mL of water, extract the aqueous phase three times with ethyl acetate, and use 25mL of ethyl acetate each time. Combine the organic phases, wash twice with saturated sodium chloride solution, add anhydrous sodium sulfate to dry, evaporate the solvent, and separate by column chromatography [V (dichloromethane): V (methanol) = 100: 1-10: 1] to obtain the target product 3,3-dimethyl-N-(4-(5-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)phenyl)butanamide, recorded as compound 2.1, mp: 213–215°C; 57%; 1H NMR (300MHz, CDCl3) δ8.25(s,1H),7.63(s,4H),7.59–7.45(m,2H),7.18(s,1H),6.96–6.89(m,2H),6.93(s,1 ES-MS m / z 473.3[M+H + ].

[0150] The structural formula of compound 2.1 is

[0151] Example 3

[0152] (1) Add 30 mmol of bipinacol borate and 40 mL of 1,4-dioxane to a 250 mL three-necked flask, and add 1 mmol of tetrakistriphenylphosphine palladium (Pd(PPh)) under nitrogen protection. 3 ) 4 , 60mmol potassium acetate and 20mmol p-bromonitrobenzene, stir and heat to 100℃ and reflux for 12h, then cool the reaction solution to room temperature, add 30mmol 2,4-dichloro-5-methylpyrimidine and 24mL saturated aqueous sodium carbonate solution under nitrogen protection, stir and heat to 108℃, reflux for 7h to stop the reaction, add 200mL water, extract with ethyl acetate three times, the amount of ethyl acetate added each time is 100mL, combine the organic phases, add anhydrous sodium sulfate to dry, evaporate the solvent, separate by column chromatography [V(petroleum ether): V(ethyl acetate)=4:1], and obtain the target product 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine, mp: 118–120℃; 73%; 1 HNMR (300MHz, CDCl3) δ8.60(d,J=0.7Hz,1H),8.44–8.34(m,2H),7.89–7.79(m,2H),2.41(d,J=0.7Hz,3H); ES-MS m / z 250.1[M+H + ].

[0153] The structural formula of 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine is

[0154] (2) 9.16 mmol 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine and 10 mL methanol were added to a 25 mL round-bottom flask. Palladium-carbon catalyst (200 mg, palladium content of 10 wt%) was added under nitrogen protection, and hydrogen (5 bar) was introduced. The reaction was stopped after stirring at room temperature for 10 h. The palladium-carbon was then filtered out using diatomaceous earth. The solvent was evaporated under reduced pressure. The aqueous phase was extracted three times with ethyl acetate, and the amount of ethyl acetate used for each extraction was 20 mL. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The crude product was separated by silica gel column chromatography [V (petroleum ether): V (ethyl acetate) = 1:1] to obtain the target product 4-(2-chloro-5-methylpyrimidin-4-yl)aniline, mp: 117–119°C; 65%; 1 H NMR (300MHz, CDCl3) δ8.39(s,1H),7.66–7.49(m,2H),6.85–6.67(m,2H),2.41(s,3H); ES-MS m / z 220.1[M+H + ].

[0155] The structural formula of 4-(2-chloro-5-methylpyrimidin-4-yl)aniline is

[0156] (3) Compound 7 (3.066 g, 14 mmol) was weighed and added to a 250 mL round-bottom flask. 70 mL of dichloromethane was added to dissolve it, and 3-phenylpropionic acid (2.628 g, 17.5 mmol), EDCI (4.026 g, 21 mmol), and DMAP (855 mg, 7 mmol) were added in sequence and stirred at room temperature. After TLC monitoring, 350 mL of water was added, and the aqueous phase was extracted three times with dichloromethane. The amount of dichloromethane used for each extraction was 175 mL. The organic phases were combined, washed twice with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was evaporated. The target product N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)-3-phenylpropanamide was obtained by column chromatography separation [V (petroleum ether): V (ethyl acetate) = 2:1], mp: 107–109 °C; 80%; 1 HNMR(300MHz, CDCl3)δ8.45(s,1H),7.65–7.59(m,5H),7.36–7.27(m,2H),7.29 –7.22(m,2H),3.07(t,J=7.5Hz,2H),2.70(t,J=7.5Hz,2H),2.38(s,3H); ES-MS m / z 352.1[M+H + ].

[0157] The structural formula of N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)-3-phenylpropanamide is

[0158]

[0159] (4) Weigh 1 mmol of the compound (2-chloro-5-methylpyrimidin-4-yl)phenyl)-3-phenylpropanamide into a 50 mL round-bottom flask, add 10 mL of 1,4-dioxane to dissolve it, and then add 1.6 mmol of TsOH·H 2 O, 4mmol 4-(pyrrolidin-1-ylsulfonyl)aniline, heated to 95℃ and refluxed for 12h, TLC monitored the complete consumption of the raw materials, the reaction was stopped, the solvent was evaporated, 30mL of water was added, the aqueous phase was extracted with dichloromethane three times, the amount of dichloromethane used for each extraction was 20mL, the organic phases were combined, dried over anhydrous sodium sulfate, and the organic phase was evaporated to dryness under reduced pressure. The target product N-(4-(5-methyl-2-((4-(pyrrolidin-1-ylsulfonyl)phenyl)amino)pyrimidin-4-yl)phenyl)-3-phenylpropanamide was obtained by column chromatography separation [V(petroleum ether):V(ethyl acetate):V(acetone)=5:1:1], and recorded as compound 3, mp: 145–147℃; 32%; 1 H NMR (300MHz, CDCl3) δ8.36(s,1H),7.85–7.78(m,2H),7.79–7.71(m,2H),7.67–7.54(m,5H),7.29(d,J=7.1Hz,2H),7.25 ES-MS m / z 542.2[M+H + ].

[0160] The structural formula of compound 3 is

[0161] Example 4

[0162] (1) Add 30 mmol of bipinacol borate and 40 mL of 1,4-dioxane to a 250 mL three-necked flask, and add 1 mmol of tetrakistriphenylphosphine palladium (Pd(PPh)) under nitrogen protection. 3 ) 4, 60mmol potassium acetate and 20mmol p-bromonitrobenzene, stir and heat to 98℃ and reflux for 8h to stop the reaction, cool the reaction solution to room temperature, add 30mmol 2,4-dichloro-5-methylpyrimidine and 24mL saturated aqueous sodium carbonate solution under nitrogen protection, stir and heat to 100℃, reflux for 10h to stop the reaction, add 200mL water, extract with ethyl acetate three times, the amount of ethyl acetate added each time is 100mL, combine the organic phases, add anhydrous sodium sulfate to dry, evaporate the solvent, separate by column chromatography [V(petroleum ether): V(ethyl acetate) = 4:1], and obtain the target product 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine, mp: 118–120℃; 73%; 1 H NMR (300MHz, CDCl3) δ8.60(d,J=0.7Hz,1H),8.44–8.34(m,2H),7.89–7.79(m,2H),2.41(d,J=0.7Hz,3H); ES-MS m / z 250.1[M+H + ].

[0163] The structural formula of 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine is

[0164] (2) Weigh 1 mmol of the compound 2-chloro-5-methyl-4-(4-nitrophenyl)pyrimidine and add it to a 50 mL round-bottom flask. Add 2 mL of 1,4-dioxane to dissolve it, and then add 0.8 mmol of TsOH·H 2 O, 1.6mmol 3-(morpholinesulfonyl)benzene, heated to 96℃, refluxed for 11h, TLC monitored the complete consumption of the raw materials, the reaction stopped, the solvent was evaporated, 20mL of water was added, the aqueous phase was extracted three times with dichloromethane, the amount of dichloromethane used for each extraction was 20mL, the organic phases were combined, dried over anhydrous sodium sulfate, and the organic phase was evaporated to dryness under reduced pressure. The target product 5-methyl-N-(3-(morpholinesulfonyl)phenyl)-4-(4-nitrophenyl)pyrimidin-2-amine was obtained by column chromatography separation [V(petroleum ether):V(ethyl acetate):V(acetone)=5:1:1], mp:196–198℃; 90%; 1 HNMR (300 MHz, DMSO-d 6 )δ10.12(s,1H),8.57(s,1H),8.44(t,J=1.9Hz,1H),8.41–8.32(m,2H),8.02–7.91(m,3H),7 .55(t,J=8.0Hz,1H),7.29–7.23(m,1H),3.62–3.54(m,4H),2.87–2.79(m,4H),2.26(s,3H); 13C NMR (75 MHz, DMSO-d 6 )δ162.3,160.5,158.0,147.6,144.0,141.4,134.6,130.0,129.4,123.2,122.5,119.6,119.1,116.6,65.1,45.8,15.4; ES-MS m / z 456.4[M+H + ].

[0165] The structural formula of 5-methyl-N-(3-(morpholinesulfonyl)phenyl)-4-(4-nitrophenyl)pyrimidin-2-amine is

[0166]

[0167] (3) Weigh 3mmol of compound 5-methyl-N-(3-(morpholinesulfonyl)phenyl)-4-(4-nitrophenyl)pyrimidin-2-amine, 12mmol of iron powder, 9mmol of ammonium chloride, 30mL of ethanol, and 7.5mL of water, and add them into a 100mL round-bottom flask in sequence. Heat to 75°C under stirring, reflux for 3h to stop the reaction, filter the reaction solution with diatomaceous earth, rinse the filter cake with 400mL of ethanol, and evaporate the filtrate. Add 300mL of water, extract the aqueous phase with ethyl acetate three times, and the amount of ethyl acetate used for each extraction is 150mL. Combine the organic phases, wash twice with saturated sodium chloride solution, add anhydrous sodium sulfate to dry, evaporate the solvent, and separate by column chromatography [V(petroleum ether): V(ethyl acetate) = 2:1] to obtain the target product 4-(4-aminophenyl)-5-methyl-N-(3-(morpholinesulfonyl)phenyl)pyrimidin-2-amine, mp: 196–198°C; 81%; 1 H NMR (300 MHz, DMSO-d 6 )δ9.83(s,1H),8.61(s,1H),8.34(s,1H),7.94–7.80(m,1H),7.64–7.46(m,3H),7.32–7.13(m ,1H),6.66(d,J=8.6Hz,2H),5.58(s,2H),3.66–3.53(m,4H),2.90–2.82(m,4H),2.30(s,3H); 13 C NMR (75 MHz, DMSO-d 6 )δ164.0,159.5,158.0,150.1,142.0,134.6,130.2,129.2,124.7,122.2,119.1,117.8,116.1,112.8,65.1,45.8,16.8; ES-MS m / z 426.4[M+H + ].

[0168] The structural formula of 4-(4-aminophenyl)-5-methyl-N-(3-(morpholinesulfonyl)phenyl)pyrimidin-2-amine is

[0169]

[0170] (4) Weigh 0.235 mmol of the compound 4-(4-aminophenyl)-5-methyl-N-(3-(morpholinesulfonyl)phenyl)pyrimidin-2-amine into a 25 mL round-bottom flask, add 5 mL of N,N-dimethylformamide to dissolve it, and then add 0.235 mmol of triethylamine, 0.47 mmol of 1-isocyanato-4-methylbenzene was reacted for 40 hours under ice bath conditions, and then the reaction was stopped. The reaction solution was evaporated to dryness, 50 mL of water was added, and the aqueous phase was extracted with ethyl acetate three times, with 25 mL of ethyl acetate used for each extraction. The organic phases were combined, washed twice with saturated sodium chloride solution, dried with anhydrous sodium sulfate, and the solvent was evaporated to dryness. The target product 1-(4-(5-methyl-2-((3-(morpholinesulfonyl)phenyl)amino)pyrimidin-4-yl)phenyl)-3-(p-tolyl)urea was obtained by column chromatography separation [V(petroleum ether):V(ethyl acetate)=2:1], recorded as compound 4, mp: 187–189°C; 71%; 1 H NMR (300 MHz, DMSO-d 6 )δ9.96(s,1H),8.91(s,1H),8.64(s,1H),8.60–8.53(m,1H),8.45(s,1H),7.94–7.87(m,1H),7.72(d,J=8.7Hz,2H),7.64–7.49(m,3 H),7.37(d,J=8.4Hz,2H),7.26–7.21(m,1H),7.10(d,J=8.4Hz,2H),3.62–3.56(m,4H),2.89–2.82(m,4H),2.30(s,3H),2.25(s,3H); 13 CNMR (75MHz, DMSO-d 6 )δ163.9,160.1,158.2,152.5,141.9,141.1,137.0,134.7,131.1,130.9,129.7,12 9.4,129.2,122.5,119.5,118.7,118.4,117.4,116.5,65.3,46.0,20.4,16.4; ES-MS m / z 559.8[M+H + ].

[0171] The structural formula of compound 4 is

[0172] Example 5

[0173] (1) Weigh 0.236 mmol of 4-(4-aminophenyl)-5-methyl-N-(3-(morpholinesulfonyl)phenyl)pyrimidin-2-amine prepared in step (3) of Example 4, add it to a 25 mL round-bottom flask, add 5 mL of dichloromethane to dissolve it, and then add 0.704 mmol 0.352mmol EDCI, 0.12mmol DMAP, stirred at room temperature for 96h. After the reaction was stopped, 35mL of water was added, and the aqueous phase was extracted three times with dichloromethane, with 15mL of dichloromethane used each time. The organic phases were combined, washed twice with saturated sodium chloride solution, dried with anhydrous sodium sulfate, and the solvent was evaporated. The target product N-(4-(5-methyl-2-((3-(morpholinesulfonyl)phenyl)amino)pyrimidin-4-yl)phenyl)nicotinamide was obtained by column chromatography separation [V(petroleum ether):V(ethyl acetate)=2:1], recorded as compound 5.1, mp: 186–188℃; 64%; 1 HNMR (300 MHz, DMSO-d 6 )δ10.68(s,1H),10.03(s,1H),9.27–9.08(m,1H),8.88–8.76(m,1H),8.62(s,1H),8.51(s,1H),8.40–8.30(m,1H),8.00–7. 90(m,3H),7.82(d,J=8.7Hz,2H),7.66–7.51(m,2H),7.34–7.22(m,1H),3.73–3.52(m,4H),2.99–2.79(m,4H),2.34(s,3H); 13 C NMR (75 MHz, DMSO-d 6 )δ164.3,163.7,160.2,158.2,152.2,148.8,141.9,139.9,135.6,134.6,133.4,130 .5,129.5,129.4,123.5,122.6,119.7,119.5,118.8,116.5,65.3,46.0,16.2; ES-MS m / z531.5[M+H + ].

[0174] The structural formula of compound 5.1 is

[0175] According to the preparation method disclosed in Example 2, the following compounds can be prepared by selecting corresponding raw materials:

[0176]

[0177]

[0178] According to the preparation method disclosed in Example 5, the following compounds can be prepared by selecting corresponding raw materials:

[0179]

[0180]

[0181] Experimental Example 1

[0182] To evaluate the selective inhibitory ability of the novel pyrimidine biphenyl derivatives in an in vitro human pancreatic cancer cell model, we performed inhibition experiments in MIApaca-2 and BXPC-3 tumor cells.

[0183] Cells used in the experiment: human pancreatic ductal adenocarcinoma (PDAC) cell line (MIApaca-2 cells) that depends on the oncogenic Kras gene for survival and a cell line expressing the wild-type Kras gene (BxPC-3 cells).

[0184] Experimental method: MIApaca-2 cells and BxPC-3 cells in the logarithmic growth phase were prepared into 1×10 4 pc·mL -1 100 μL of the cell suspension was inoculated into each well of a 96-well plate and incubated at 5% CO 2 , cultured at 37℃ for 48 hours until the bottom is completely covered, the supernatant is removed, and 200μL of gradient concentrations of drug-containing culture medium are added to each well (the compound storage solution dissolved in DMSO is diluted with complete culture medium to the required concentration, where the final concentration of DMSO is 0.1% and the final concentration of serum is 2%), 3 replicates are set for each concentration, and blank control wells (no cells, solvent control group) and negative control wells (cells and equal volume of solvent) are set, and 3 replicates are set. After adding the drug, continue to culture for 48 hours. After terminating the culture, replace the fresh culture medium (remove the culture medium, wash the cells twice with the culture medium, and then add new culture medium) to remove the influence of the drug. Add 10% CCK-8 solution to each well, color at 37℃ for 1 to 4 hours, and measure the absorbance at 450nm of each well every half an hour. Calculate the inhibition rate of the compound for 48 hours according to the following formula, and calculate the half inhibition concentration (IC50).

[0185] Cell viability (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100

[0186] A (drug added): absorbance of wells with cells, CCK-8 solution, and drug solution

[0187] A (blank): absorbance of wells with culture medium and CCK-8 solution but no cells

[0188] A (0 drug addition): absorbance of wells with cells, CCK-8 solution but no drug solution. The specific experimental results are as follows:

[0189] The half-maximal inhibitory concentration (IC50) values ​​of compounds 2.1, 2.2, 2.3, 2.4, 2.6, 2.7, 2.8, 2.9, 4, 5.1, and 5.2 on MIAPaCa-2 or BxPC-3 cells were lower than 10 μM.

[0190] Although the half-maximal inhibitory concentration (IC50) values ​​of compounds 2.5, 1, 3, and 5.3 on MIAPaCa-2 or BxPC-3 cells were higher than 10 μM, they were lower than 100 μM, indicating that they also had a certain inhibitory effect.

[0191] Among them, compounds 2.1, 2.2, 2.4, 2.8, 4, 5.1, and 5.2 had better effects on MIAPaCa-2 cells than BxPC-3 cells.

[0192] Experimental Example 2

[0193] In order to verify the ability of the compound XL-1063 (compound 2.1) with the strongest cell inhibitory ability to inhibit protein interaction, an immunoaffinity inhibition potency evaluation experiment was performed:

[0194] Experimental method: XL-1063 solution was diluted with buffer PBS to obtain the corresponding concentration gradient (0.5μg / mL, 5μg / mL, 50μg / mL, 500μg / mL). Raman detection was performed in parallel. 150μL of silver probe (unlabeled 4-MBA) was added to each well, and different concentrations of small molecule compound XL-1063 were added accordingly. Then 50μL of magnetic probe was added to each well, reacted for 1h, magnetically separated and washed 3 times, and resuspended with PBS buffer. 2μL of 4-MBA (1.0mmol / L) was added to each well to react for 1 hour, magnetically separated and washed 3 times, resuspended with PBS buffer and SERS detection was performed in situ after enrichment in an external magnetic field. During data processing, three batches of detection were performed for each small molecule, and each detection was measured in parallel for more than three times. After processing with NGSLabSpec software, the final spectrum data of each well was processed and plotted.

[0195] The specific process is as follows:

[0196] (1) Blank control: immunoaffinity structures of Kras4B and PDEδ.

[0197] The Raman probe was prepared before use. The silver probe and the magnetic probe were mixed in a 96-well plate at a volume ratio of 150 μL:50 μL and an equal amount of PBS buffer was added. After incubation for 60 minutes, in situ cleaning and magnetic aggregation were performed, and 2 μL 4-MBA (1.0 mM) was added to react for 1 hour. The sample was magnetically separated and washed 3 times, resuspended with PBS buffer and enriched in an external magnetic field for in situ SERS detection.

[0198] (2) Experimental group: evaluation of small molecule immunoaffinity inhibitory efficacy.

[0199] Accurately pipette 150 μL of silver probe and 50 μL of magnetic probe, add different concentrations of XL-1063 at the same time, incubate for 60 minutes, incubate the signal molecules and wash according to the above operation, and perform Raman signal detection in a 96-well plate.

[0200] The exposure time was set to 1 second and the number of exposures was set to 10 times and the average was taken.

[0201] The specific experimental results are as follows Figure 1 As shown, Figure 1 A in the figure is a comparison of the SERS spectra of the silver magnetic probe mixture after being treated with gradient concentrations of XL-1063 (0-500 μg / mL). Figure 1 B in the figure is a histogram at the point where the SERS intensity is maximum. It can be seen from the figure that the Raman signal gradually weakens as the concentration of XL-1063 increases, confirming that the small molecule XL-1063 can regularly inhibit the protein interaction between Kras4B and PDEδ, and is indeed a potential small molecule inhibitor.

[0202] Experimental Example 3

[0203] In order to verify the ability of XL-1063, the compound with the strongest cell inhibitory ability, to inhibit protein interaction, an immunoaffinity inhibition potency evaluation experiment was conducted. The experimental method is as follows:

[0204] The inhibitor solution was diluted with buffer PBS to obtain the corresponding concentration gradient (0.5μg / mL, 5μg / mL, 50μg / mL, 500μg / mL) of compound XL-1063 solution. Raman detection was performed in parallel. 150μL of silver probe (unlabeled 4-MBA) was added to each well, and different concentrations of small molecule compound XL-1063 were added accordingly. Then 50μL of magnetic probe was added to each well, reacted for 1h, magnetically separated and washed 3 times, and resuspended with PBS buffer. 2μL of 4-MBA (1.0mmol / L) was added to each well to react for 1 hour, magnetically separated and washed 3 times, resuspended with PBS buffer and SERS detection was performed in situ after enrichment in an external magnetic field. During data processing, three batches of detection were performed for each small molecule, and each detection was measured in parallel for more than three times. After processing with NGSLabSpec software, the final spectrum data of each well was processed and obtained. Figure 1 , Figure 1 a in the figure is a comparison of the SERS spectra of the silver magnetic probe mixture after being treated with gradient concentrations of XL-1063 (0-500 μg / mL). Figure 1 The b in the figure is the histogram at the location where the SERS intensity is maximum.

[0205] The specific process is as follows:

[0206] (1) Blank control: immunoaffinity structures of Kras4B and PDEδ.

[0207] The Raman probe was prepared before use. The silver probe and the magnetic probe were mixed in a 96-well plate at a volume ratio of 150 μL:50 μL and an equal amount of PBS buffer was added. After incubation for 60 minutes, in situ cleaning and magnetic aggregation were performed. 2 μL 4-MBA (1.0 mmol / L) was added to react for 1 hour, magnetically separated and washed 3 times, resuspended with PBS buffer and enriched in an external magnetic field for in situ SERS detection.

[0208] (2) Experimental group: evaluation of small molecule immunoaffinity inhibitory efficacy.

[0209] Accurately pipette 150 μL of silver probe and 50 μL of magnetic probe, add different concentrations of XL-1063 at the same time, incubate for 60 minutes, incubate the signal molecules and wash according to the above operation, and perform Raman signal detection in a 96-well plate.

[0210] The exposure time was set to 1 second and the number of exposures was set to 10 times and the average was taken.

[0211] The specific experimental results are as follows:

[0212] The Raman signal gradually weakened as the concentration of XL-1063 increased, confirming that the small molecule XL-1063 can regularly inhibit the protein interaction between Kras4B and PDEδ, and is indeed a potential small molecule inhibitor.

[0213] Experimental Example 4

[0214] Cells used in the experiment: human pancreatic ductal adenocarcinoma (PDAC) cell line (MIApaca-2) that depends on the oncogenic Kras gene for survival, and a cell line expressing the wild-type Kras gene (BxPC-3 cells).

[0215] To evaluate the antitumor activity of XL-1063, we established nude mouse models with human BXPC-3 and MIApaca-2 tumor cell xenografts.

[0216] Experimental method: Tumor cells were injected subcutaneously on the back of nude mice and the growth rate of the tumor was monitored. When the tumor size reached 125 mm 3After the size was measured, the BXPC-3 and MIApaca-2 model groups were randomly divided into five groups, with seven mice in each BXPC-3 (control group) and ten mice in each MIApaca-2 (experimental group). The detailed grouping is as follows:

[0217] BXPC-3 control group

[0218] (a) Model control group;

[0219] (b) Positive control group (15 mg / kg Deltarasin) QD ip;

[0220] (c) Model + low-dose drug (7.5 mg / kg XL-1063) QD ip;

[0221] (d) Model + medium dose drug (15 mg / kg XL-1063) QD ip;

[0222] (e) Model + high dose drug (20 mg / kg XL-1063) QD ip

[0223] MIApaca-2 experimental group

[0224] (a) Model control group;

[0225] (b) Positive control group (15 mg / kg Deltarasin) QD ip;

[0226] (c) Model + low-dose drug (3.75 mg / kg XL-1063) QD ip;

[0227] (d) Model + medium dose drug (7.5 mg / kg XL-1063) QD ip;

[0228] (e) Model + high dose drug (15 mg / kg XL-1063) QD ip

[0229] Mice were treated for 14 days (MIAPaca-2) and 21 days (BXPC-3). The mice were weighed and tumor size was measured every three to four days. Two-dimensional tumors were measured with a vernier caliper, and tumor volume was estimated based on the measurements using the following formula: tumor volume (TV) (mm 3 ) = [length (mm) × width (mm)2] / 2.

[0230] When the tumor volume reached 1000 cubic millimeters, the treatment of mice was stopped. The mice were euthanized the next day after drug withdrawal, the tumor was removed, the mice and the tumor were weighed, photos were taken, and the tumor inhibition rate and body weight change were calculated.

[0231] The drug was administered once daily (QD) by intraperitoneal injection in the right side of the body. Three dose regimens of XL-1063 were tested in both the experimental and control groups.

[0232] The tumor growth inhibition of tumor volume (TGItv) was calculated as follows: TGItv = [1-(average TV in the treatment group during the experiment-average TV at the beginning of the treatment group / average TV in the control group during the experiment-average TV at the beginning of the control group)] × 100%

[0233] The tumor growth inhibition of tumor weight (TGItw) was calculated as follows: TGItw = [1-(average tumor weight of the control group-average tumor weight of the drug-treated group / average tumor weight of the control group)] × 100%

[0234] All data results are presented as mean ± standard error. Statistical analysis was performed using Excel 2019. Tumor volume and tumor mass among groups were compared using Student's t test. P < 0.05 was considered statistically significant. Graphpad Prism 8.0 software was used for plotting.

[0235] The excised tumors were stained with hematoxylin and eosin, and immunohistochemically stained for the cell proliferation-related index MKi-67 (Ki-67) and the epithelial differentiation-related marker cytokeratin 19 (CK19).

[0236] The specific experimental results are as follows Figure 2 , Figure 3 As shown, the appearance of tumors in each group was observed at the end of the experiment ( Figure 2 a and Figure 3 In A), the tumor volume of the experimental group after XL-1063 treatment was significantly lower than that of the control group, while there was no significant difference in the control group, which preliminarily indicated that XL-1063 had higher selectivity and better anti-Kras-dependent PDAC tumor activity.

[0237] Table 1 The efficacy of different doses of XL-1063 on BXPC-3 model mice

[0238]

[0239] Table 2 The efficacy of different doses of XL-1063 on MIApaca-2 model mice

[0240]

[0241] (a : Compared with the control group)

[0242] As shown in Table 1 and Table 2: For the control group, the tumor inhibition rate of the positive drug Deltarasin was higher than that of XL-1063 at the same concentration at the end of treatment. For the experimental group, the tumor inhibition rate of the positive drug Deltarasin was much lower than that of XL-1063 at the same concentration at the end of treatment, and the low-dose XL-1063 still had an excellent tumor inhibition rate. Only in the experimental group, the therapeutic effect of high-dose XL-1063 was significantly different from that of the model control (p<0.05), indicating that XL-1063 has a good therapeutic effect on the corresponding PDAC.

[0243] The mice in the positive control group treated with deltarasin had a significant decrease in body weight ( Figure 2 d) in. Figure 3 The results of the in vivo inhibition experiment of XL-1063 on MIApaca-2 cell line; Figure 3 A in the figure is the tumor tissue photos obtained from each group; Figure 3 B in the figure is the curve of the volume change of tumor tissue in each group over time; Figure 3 C in the figure is the volume statistics of tumor tissues in each group; Figure 3 D in the figure is the curve of weight change of animals in each group over time; Figure 3 E in the figure is the statistical chart of the weight of animals in each group; Figure 3 F in the figure is a statistical graph of tumor tissue weight in each group. It can be seen from the figure that compared with the model control group, the tumor growth rate and tumor volume of the MIAPaca-2 group of mice treated with XL-1063 were significantly reduced. The results of the study indicate that inhibiting the PDEδ-Kras4B interaction by small molecules affects the spatial organization of Kras-dependent tumors, providing a new opportunity to inhibit oncogenic RAS signals and thus inhibit tumor growth.

[0244] The results of hematoxylin and eosin staining and immunohistochemical analysis showed that compared with the insensitive BxPC-3 tumor model group ( Figure 4 ), the proportion of necrotic tissue in MIApaca-2 tumor tissue treated with positive drugs and XL-1063 increased, the number of tumor cells decreased, the expression of Ki-67 and CK 19 decreased significantly, and the number and intensity of Ki-67 staining related to proliferation were significantly lower than those in the model control and the positive control group; CK19 was strongly and diffusely expressed in the model control, while it was weakly expressed in MIApaca-2 tumor tissue treated with XL-1063, and was significantly weaker than the positive control group. It proves that the proliferation and migration abilities of tumors are inhibited, and the inhibitory effect of the XL-1063 group is stronger than that of the positive drug group ( Figure 5). In insensitive tumor tissues, the situation is slightly different. The positive drug group showed stronger inhibition ability, proving that the positive drug has poor selectivity, and XL-1063 is a candidate small molecule inhibitor with high selectivity and lethality.

[0245] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A novel pyrimidine biphenyl derivative having antitumor activity, characterized in that: The structural formula of the novel pyrimidine biphenyl derivative having anti-tumor activity is shown in Formula I: The R 1 One selected from the group consisting of methyl, deuterated methyl and fluoromethyl; The R 2 One selected from the group consisting of hydrogen, deuterium, halogen, alkyl and alkoxy; The R 3 , R 4 , R 6 , R 7 , R 9 , R 10 , R 12 and R 13 is independently selected from one of hydrogen, deuterium, halogen, hydroxyl, amine, cyano, sulfonamide, C1-C3 alkyl and C1-C3 alkoxy; The R 5 One selected from 4-7 membered cyclic amine, 4-7 membered heterocyclic amine and sulfonyl, wherein the 4-7 membered cyclic amine, 4-7 membered heterocyclic amine and sulfonyl independently contain 1, 2 or 3 R a Substituents; The R 8 One selected from hydrogen, deuterium and C1-C6 alkyl; The R 11 Selected from -N(R b )C(=O)R c 、-N(R b )S(=O)2R c 、-C(=O)NR b R c and -S(=O)2NR b R c One of; Among them, R a One selected from hydrogen, deuterium, halogen, hydroxyl, amine, cyano, sulfonamide, C1-C6 alkyl and C1-C6 alkoxy; R b One selected from hydrogen, deuterium and C1-C6 alkyl; R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituent.

2. The method for preparing the novel pyrimidine biphenyl derivative with antitumor activity according to claim 1, characterized in that: The following steps are involved: 1) An organic solvent, a catalyst I and potassium acetate are mixed and reacted to obtain a mixture; 2) The mixture obtained in step 1) is mixed with Mix with sodium carbonate solution and continue to react to obtain the intermediate 3) The intermediate and Catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate are mixed to obtain the target product 3. The method for preparing the novel pyrimidine biphenyl derivative with antitumor activity according to claim 2, characterized in that: In the step 1) The addition ratio of organic solvent, catalyst I and potassium acetate is 1 mmol: 1.1~2mmol: 2~10mL: 0.01~0.1mmol: 2~4mmol; The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol; The catalyst I is tetrakistriphenylphosphine palladium; The reaction temperature in step 1) is 95-110° C. and the reaction time is 4-12 hours.

4. The method for preparing the novel pyrimidine biphenyl derivative with antitumor activity according to claim 3, characterized in that: In the step 2) The molar volume ratio of sodium carbonate solution is 3-4 mmol: 2.4-3 mL; Said and The molar ratio is 1.2 to 2:1; The sodium carbonate solution is a saturated sodium carbonate solution; The reaction temperature in step 2) is 95-110° C. and the reaction time is 4-12 hours.

5. The method for preparing the novel pyrimidine biphenyl derivative with antitumor activity according to claim 4, characterized in that: In step 3) The molar volume ratio of catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate is 1-1.5 mmol: 1 mmol: 0.1-0.5 mmol: 0.1-0.5 mmol: 1-5 mL: 2-4 mmol; The catalyst II is Pd2(dba)3; The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol; The reaction temperature in step 3) is 80-100° C., and the reaction time is 4-12 hours.

6. The method for preparing a novel pyrimidine biphenyl derivative having antitumor activity according to any one of claims 2 to 5, characterized in that: The reactions in steps 1) to 3) are independently carried out under an inert atmosphere.

7. The method for preparing the novel pyrimidine biphenyl derivative with antitumor activity according to claim 1, characterized in that: The following steps are involved: 1) An organic solvent, a catalyst I and potassium acetate are mixed and reacted to obtain a mixture; 2) The mixture obtained in step 1) is mixed with Mix with sodium carbonate solution and continue to react to obtain the intermediate 3) The intermediate and Catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate are mixed to obtain the target product 4) Mix with organic solvent and palladium carbon catalyst and introduce hydrogen to react to obtain intermediate product 5) The intermediate product Reaction with acid compounds to obtain the target product In the step 5), the acid compound is a carboxylic acid compound or a sulfonic acid compound; The carboxylic acid compound is HOOC-R c , where R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituents; The sulfonic acid compound is HOS(=O)2-R c , where R c One selected from C1-C8 alkyl, phenyl and 5-6 membered heteroaryl, wherein C1-C8 alkyl, phenyl and 5-6 membered heteroaryl independently contain 1, 2 or 3 R a Substituent.

8. The method for preparing a novel pyrimidine biphenyl derivative having antitumor activity according to claim 7, characterized in that: In the step 1) The addition ratio of organic solvent, catalyst I and potassium acetate is 1 mmol: 1.1~2mmol: 2~10mL: 0.01~0.1mmol: 2~4mmol; The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol; The catalyst I is tetrakistriphenylphosphine palladium; The reaction temperature in step 1) is 95-110° C. and the reaction time is 4-12 hours; In the step 2) The molar volume ratio with sodium carbonate solution is 1.2-1.5mmol:1mL; Said and The molar ratio is 1.2 to 2:1; The sodium carbonate solution is a saturated sodium carbonate solution; The reaction temperature in step 2) is 95-110° C. and the reaction time is 4-12 hours.

9. The method for preparing a novel pyrimidine biphenyl derivative having antitumor activity according to claim 8, characterized in that: In the step 3) The molar volume ratio of catalyst II, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, organic solvent and potassium carbonate is 1-1.5 mmol: 1 mmol: 0.1-0.5 mmol: 0.1-0.5 mmol: 1-5 mL: 2-4 mmol; The catalyst II is Pd2(dba)3; The organic solvent includes one or more of 1,4-dioxane, acetonitrile, dichloromethane and tert-butyl alcohol; The reaction temperature in step 3) is 80-100°C and the reaction time is 4-12h; In the step 4) The addition ratio of organic solvent, palladium carbon catalyst and hydrogen is 1mmol:1-50mL:10-100mg:1-10bar; The reaction time in step 4) is 4 to 12 hours; In the step 5) The molar ratio with the acid compound is 1:1.2~2; The reaction time of step 5) is 8 to 48 hours.

10. Use of the novel pyrimidine biphenyl derivative with antitumor activity according to claim 1 in the preparation of antitumor drugs.

Citation Information

Patent Citations

  • 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them

    CN101421250A

  • Phenyl amino pyrimidine compounds and uses thereof

    CN104030990A

  • Diarylpyrimidine derivative containing biphenyl structure and preparation method and application thereof

    CN109053591A

  • Combinations of JAK-2 inhibitors and other agents

    WO2009017838A2

Cited By

  • Application of pyrimidine biphenyl derivative

    CN119548504A

  • Ras inhibitors

    WO2025240847A1

  • Methods of treating a ras protein-related disease or disorder

    WO2025255438A1

  • Therapeutic compositions and methods for managing treatment-related effects

    WO2025265060A1

  • Ras inhibitors

    WO2026006747A1